Quantitative Investment Management LLC Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Quantitative Investment Management LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 106.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,981 shares of the biopharmaceutical company’s stock after buying an additional 4,124 shares during the quarter. Quantitative Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $2,402,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after acquiring an additional 151,480 shares during the period. Norges Bank purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $895,816,000. Orbis Allan Gray Ltd increased its stake in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. Wellington Management Group LLP lifted its position in Alnylam Pharmaceuticals by 9.0% in the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after purchasing an additional 174,482 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in Alnylam Pharmaceuticals by 8.3% in the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock valued at $382,339,000 after purchasing an additional 73,716 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $237.10 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The stock has a market capitalization of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. The stock’s 50 day moving average price is $262.62 and its 200-day moving average price is $293.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) earnings per share. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. Needham & Company LLC cut their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Barclays lowered their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. JPMorgan Chase & Co. cut their price target on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $386.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.